Találati lista | Tudóstér

001-es BibID:	BIBFORM046437
Első szerző:	Literáti-Nagy Zsuzsanna
Cím:	A novel insulin sensitizer drug candidate-BGP-15-can prevent metabolic side effects of atypical antipsychotics / Zsuzsanna Literati-Nagy, Kálmán Tory, Botond Literáti-Nagy, Attila Kolonics, László Vígh Jr., László Vígh, József Mandl, Zoltán Szilvássy
Dátum:	2012
ISSN:	1219-4956 1532-2807
Megjegyzések:	Atypical antipsychotic drugs (AAPD) are widelyused to treat severe psychiatric disorders, have well documentedmetabolic side effects such as disturbances in glucosemetabolism, insulin resistance and weight gain. It hasbeen shown that BGP-15, a hydroxylamine derivative withinsulin sensitizing activity can prevent AAPD provoked fataccumulation in adipocyte cultures, and insulin resistance inanimal experiments and in healthy volunteers. The aim ofthis study was to compare the preventive effect of BGP-15with conventional oral antidiabetics on metabolic sideeffects of AAPDs. We found that BGP-15 that does notbelong to either conventional insulin sensitizers or oralantidiabetics, is able to counteract insulin resistance andweight gain provoked by antipsychotic agents in rats whilerosiglitazone and metformin were not effective in the applieddoses. Our results confirm that BGP-15 is a promisingnew drug candidate to control the metabolic side effects ofatypical antipsychotics. Data indicate that this rat model issuitable to analyze the metabolic side effects of AAPDs andthe protective mechanism of BGP-15.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Atypical antipsychotic drugs Side effects BGP-15 Hydroxylamine derivative Insulin resistance Weight gain Hyperinsulinaemic euglycaemic glucose clamp
Megjelenés:	Pathology & Oncology Research. - 18 : 4 (2012), p. 1071-1076. -
További szerzők:	Tory Kálmán Literáti-Nagy Botond Kolonics Attila Vígh László Jr. Vígh László (orvos Szeged) Mandl József Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM046410
Első szerző:	Literáti-Nagy Zsuzsanna
Cím:	Synergetic Insulin Sensitizing Effect of Rimonabant and BGP-15 in Zucker-Obes Rats / Zsuzsanna Literati-Nagy, Kálmán Tory, Botond Literáti-Nagy, Ágnes Bajza, László Vígh Jr., László Vígh, József Mandl, Zoltán Szilvássy
Dátum:	2013
ISSN:	1219-4956 1532-2807
Megjegyzések:	Abdominal obesity is referred for as a commonpathogenic root of multiple risk factors, which include insulinresistance, dyslipidemia, hypertension, and a pro-atherogenicand pro-inflammatory state. Irrespective of its psychiatric sideeffects, rimonabant through blocking cannabinoid-1 receptor(CB1R) induces an increase in whole body insulin sensitivity.The aim of this work was to study the effect of selected dosesof another insulin sensitizer compound BGP-15, andrimonabant on insulin resistance in Zucker obese rats with apromise of inducing insulin sensitization together at lowerdoses than would have been expected by rimonabant alone.We found that BGP-15 potentiates the insulin sensitizing effectof rimonabant. The combination at doses, which do not induceinsulin sensitization by themselves, improved insulin signaling.Furthermore our results suggest that capsaicin-inducedsignal may play a role in insulin sensitizing effect of bothmolecules. Our data might indicate that a lower dose ofrimonabant in the treatment of insulin resistance and type 2diabetes is sufficient to administer, thus a lower incidence ofthe unfavorable psychiatric side effects of rimonabant are to beexpected.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Rimonabant BGP-15 Insulin resistance Obesity Capsaicin Glucose clamp
Megjelenés:	Pathology & Oncology Research. - 12253 (2013), p. 1-5. -
További szerzők:	Tory Kálmán Literáti-Nagy Botond Bajza Ágnes (1970-) (biológus) Vígh László Jr. Vígh László (orvos Szeged) Mandl József Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM083187
035-os BibID:	(PMID)31968693 (WoS)000515381800190 (Scopus)85078179453
Első szerző:	Pető Ágota (gyógyszerész)
Cím:	Pharmacological Overview of the BGP-15 Chemical Agent as a New Drug Candidate for the Treatment of Symptoms of Metabolic Syndrome / Ágota Pető, Dóra Kósa, Pálma Fehér, Zoltán Ujhelyi, Dávid Sinka, Miklós Vecsernyés, Zoltán Szilvássy, Béla Juhász, Zoltán Csanádi, László Vígh, Ildikó Bácskay
Dátum:	2020
ISSN:	1420-3049
Megjegyzések:	BGP-15 is a new insulin sensitizer drug candidate, which was developed by Hungarian researchers. In recent years, numerous research groups have studied its beneficial effects. It is effective in the treatment of insulin resistance and it has protective effects in Duchenne muscular dystrophy, diastolic dysfunction, tachycardia, heart failure, and atrial fibrillation, and it can alleviate cardiotoxicity. BGP-15 exhibits chemoprotective properties in different cytostatic therapies, and has also proven to be photoprotective. It can additionally have advantageous effects in mitochondrial-stress-related diseases. Although the precise mechanism of the effect is still unknown to us, we know that the molecule is a PARP inhibitor, chaperone co-inducer, reduces ROS production, and is able to remodel the organization of cholesterol-rich membrane domains. In the following review, our aim was to summarize the investigated molecular mechanisms and pharmacological effects of this potential API. The main objective was to present the wide pharmacological potentials of this chemical agent.
Tárgyszavak:	Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk BGP-15 PARP inhibitor chaperone co-inducer insulin sensitizer
Megjelenés:	Molecules. - 25 : 2 (2020), p. 429-441. -
További szerzők:	Kósa Dóra (1994-) (gyógyszerész) Fehér Pálma (1976-) (gyógyszerész) Ujhelyi Zoltán (1984-) (gyógyszerész) Sinka Dávid Zsolt (1991-) (gyógyszerész) Vecsernyés Miklós (1959-) (gyógyszertechnológus, endokrinológus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Juhász Béla (1978-) (kísérletes farmakológus) Csanádi Zoltán (1960-) (kardiológus) Vígh László (orvos Szeged) Bácskay Ildikó (1969-) (gyógyszerész, gyógyszertechnológus)
Pályázati támogatás:	NKFIH-1150-6/2019 Egyéb EFOP-3.6.1-16-2016-00022 EFOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM028449
Első szerző:	Szilvássy Zoltán (belgyógyász, farmakológus, klinikai farmakológus)
Cím:	Insulin resistance occurs in parallel with sensory neuropathy in streptozotocin-induced diabetes in rats : differential response to early vs late insulin supplementation / Szilvássy Z., Németh J., Kovács P., Paragh G., Sári R., Vígh L., Peitl B.
Dátum:	2012
Megjegyzések:	We investigated whether progressive sensory neuropathy was accompanied by changes in whole-body insulin sensitivity (WBIS) in rats made diabetic by streptozotocin (STZ). The effects of early and late insulin supplementation were also studied. The STZ-treated rats failed to gain weight and exhibited stable hyperglycemia and low plasma insulin levels with a decrease in nerve conduction velocity (NCV) measured in A and C fibers of the saphenous nerve. A decreased sensory neuropeptide (SNP) release such as that of substance P, somatostatin, and calcitonin gene-related peptide determined from organ fluid of tracheal preparations subjected to electrical field stimulation also occurred in diabetic animals. These features were accompanied by a decrease in WBIS measured by hyperinsulinemic-euglycemic glucose clamping and a decrease in insulin-stimulated glucose uptake in cardiac and gastrocnemius muscle. When insulin supplementation with slow-release implants (2 IU/d) was started 4 weeks after STZ injection, blood glucose level normalized. Both insulin sensitivity and sensory nerve function reflected in either NCV or SNP release completely recovered by the 12th post-STZ week. When the insulin implants were applied from the eighth post-STZ week, both WBIS and glucose uptake remained significantly decreased, with a seriously impaired NCV and SNP release with strong hyperglycemia. Late insulin supplementation, however, even by using double implantation from the 10th post-STZ week, was unable to restore blood glucose, WBIS, NCV, and SNP release by the 12th week. Insulin resistance occurs in parallel with sensory neuropathy in STZ-diabetic rats. Both can be improved by early but not late insulin supplementation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Metabolism. - 61 : 6 (2012), p. 776-786. -
További szerzők:	Németh József (1954-) (vegyész, analitikus) Kovács Péter (1947-) (belgyógyász, kardiológus, klinikai farmakológus) Paragh György (1953-) (belgyógyász) Sári Réka (farmakológus) Vígh László (orvos Szeged) Peitl Barna (1972-) (orvos, farmakológus)
Pályázati támogatás:	TÁMOP-4.2.2.-08/1-2008-0014 TÁMOP 75965 OTKA NKFP_07-A2-2008-0260 Egyéb GOP-1.1.207/1-2008-0004 Egyéb OM00174/2008 Egyéb GOP-1.1.1-07/1-2008-0032 Egyéb GOP-1.2.1-082009-0023 Egyéb
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: